Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (258 reviews)

For research use only. Not for use in humans.

Catalog No.S1009 Synonyms: NVP-BEZ235

258 publications

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Selleck's Dactolisib (BEZ235) has been cited by 258 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )
Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )
Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )
BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )
J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )
Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	NFqzVWpCdnSrbXnjdo9jcWGuIFHzd4F6		M1fGdFE5KGh?	NIj6bWFFVVOR	NUj6UZVjSW62aYTyfZBidm:\|b33hcEBi[3Srdnn0fUB4cXSqIFXDOVAhd2ZiMD6wNFI2KM7:TR?=	M4C4UVI1QDB3OUS2
MCF7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[ybFQxNjBzLUGwNEDPxE1?	M4rDWFQ5KGh?	MoPESG1UVw>?	MWTJR\|UxRTBwN{Og{txO	M1O2UVI{QDdzOUC0
HCT116	NYn3eZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUewMlAyNTFyMDFOwG0>	MWm0PEBp	NG\IT2pFVVOR	MX7JR\|UxRTFwMU[g{txO	MmTNNlM5PzF7MES=
U87MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL5OllsOC5yMT2xNFAh\|ryP	NVy4XG5ZPDhiaB?=	NYnsUIp{TE2VTx?=	M3XTZ2lEPTB;MT6zNkDPxE1?	MUGyN\|g4OTlyNB?=
HBC4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHBO3o3OC5yMT2xNFAh\|ryP	NEXhSXQ1QCCq		M4fQfGxw\yCJSUWwQU05NjZzIF2=	NV3kfmduOjJ\|M{[yOFY>
BSY1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrF[YUyOC5yMT2xNFAh\|ryP	MlnQOFghcA>?		MmrnUI9oKEeLNUC9MVgvPDhiTR?=	NXPZc2xrOjJ\|M{[yOFY>
HBC5	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[xRlAvODFvMUCwJO69VQ>?	NEi3e\|E1QCCq		M13tN2xw\yCJSUWwQU04Njh5IF2=	M3fzblIzOzN4MkS2
MCF7	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3LdmtZOC5yMT2xNFAh\|ryP	NEPtW5c1QCCq		NWP0bYtOVG:pIFfJOVA:NThwMU[gUS=>	MX[yNlM{PjJ2Nh?=
MDA-MB-231	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnlNE4xOS1zMECg{txO	MYC0PEBp		NUPJSWtwVG:pIFfJOVA:NThwMEmgUS=>	NF7G[XEzOjN\|NkK0Oi=>
U251	M4L6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTCNE4xOS1zMECg{txO	MkfCOFghcA>?		Mnr0UI9oKEeLNUC9MVcvPjZiTR?=	MYiyNlM{PjJ2Nh?=
SF268	NYmzUpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPWNE4xOS1zMECg{txO	M3HvdVQ5KGh?		MmP0UI9oKEeLNUC9MVcvQTJiTR?=	NEnwZ4kzOjN\|NkK0Oi=>
SF295	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFqwWYgxNjBzLUGwNEDPxE1?	MWS0PEBp		NVi4eHlLVG:pIFfJOVA:NThwM{GgUS=>	MUSyNlM{PjJ2Nh?=
SF539	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSwMlAyNTFyMDFOwG0>	M{e3[FQ5KGh?		MkjmUI9oKEeLNUC9MVgvPTliTR?=	NH75cIQzOjN\|NkK0Oi=>
SNB75	NXj2VlEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGwMlAyNTFyMDFOwG0>	M4nQWVQ5KGh?		NWrie45xVG:pIFfJOVA:NThwNUigUS=>	NGDhNFUzOjN\|NkK0Oi=>
SNB78	NWLJNIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nhb\|AvODFvMUCwJO69VQ>?	MVy0PEBp		NE\EZWRNd2diR1m1NF0uQC54NTDN	MX2yNlM{PjJ2Nh?=
HCC2998	NXy2WZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmqyNE4xOS1zMECg{txO	M13Ec\|Q5KGh?		MX\Mc4chT0l3ME2tPE4xPSCP	NHHvUlIzOjN\|NkK0Oi=>
KM12	NF\nd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:wMlAyNTFyMDFOwG0>	MXe0PEBp		NHrqeJBNd2diR1m1NF0uPy53NDDN	Ml3nNlI{OzZ{NE[=
HT-29	NGHhXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfLSWg4OC5yMT2xNFAh\|ryP	NUD1R4F{PDhiaB?=		M3n1RWxw\yCJSUWwQU04Njd3IF2=	NUD6PWZvOjJ\|M{[yOFY>
HCT15	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYi2b5BzOC5yMT2xNFAh\|ryP	MWK0PEBp		NV;DfFlYVG:pIFfJOVA:NThwMEOgUS=>	NGrBR5ozOjN\|NkK0Oi=>
HCT116	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmwMlAyNTFyMDFOwG0>	NXXWPW5NPDhiaB?=		MnTOUI9oKEeLNUC9MVcvPjFiTR?=	NUfpPWtJOjJ\|M{[yOFY>
NCI-H23	M3ryNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf4[XRmOC5yMT2xNFAh\|ryP	M3LP[\|Q5KGh?		M3TPNGxw\yCJSUWwQU04NjZ2IF2=	NH:xNWEzOjN\|NkK0Oi=>
NCI-H226	NW\mT5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrSUJMxNjBzLUGwNEDPxE1?	M1;6dVQ5KGh?		Mof1UI9oKEeLNUC9MVgvPDRiTR?=	NIHYdVYzOjN\|NkK0Oi=>
NCI-H522	NWPrcWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlK3NE4xOS1zMECg{txO	NFvDcoU1QCCq		MmLIUI9oKEeLNUC9MVgvPDViTR?=	NGT0NpYzOjN\|NkK0Oi=>
NCI-H438	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP5NE4xOS1zMECg{txO	MUO0PEBp		M1r6cGxw\yCJSUWwQU05NjFzIF2=	M2S1e\|IzOzN4MkS2
A549	NF;2dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfSNE4xOS1zMECg{txO	M3XDZ\|Q5KGh?		MlvXUI9oKEeLNUC9MVgvODdiTR?=	MlfKNlI{OzZ{NE[=
DMS273	M1qw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TKOlAvODFvMUCwJO69VQ>?	M4jYR\|Q5KGh?		MorWUI9oKEeLNUC9MVcvQDBiTR?=	MmHFNlI{OzZ{NE[=
DMS114	NFfmPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDk[nYxNjBzLUGwNEDPxE1?	NWHtR21ZPDhiaB?=		NWH6T4duVG:pIFfJOVA:NThwM{mgUS=>	NXfx[JVFOjJ\|M{[yOFY>
LOXIMVI	M{TsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWi1U4czOC5yMT2xNFAh\|ryP	M37oNFQ5KGh?		NVPHVZlpVG:pIFfJOVA:NThwNk[gUS=>	NVnsOohDOjJ\|M{[yOFY>
OVCAR3	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LRe\|AvODFvMUCwJO69VQ>?	M1zMRVQ5KGh?		M3SwfGxw\yCJSUWwQU05NjF5IF2=	MkfhNlI{OzZ{NE[=
OVCAR4	NX3kT3VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nINVAvODFvMUCwJO69VQ>?	M1jPUFQ5KGh?		NUnkZpRvVG:pIFfJOVA:NThwNUigUS=>	MWqyNlM{PjJ2Nh?=
OVCAR5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3W2NlAvODFvMUCwJO69VQ>?	NEDXOFM1QCCq		MlXHUI9oKEeLNUC9MVcvPTdiTR?=	Mn2wNlI{OzZ{NE[=
OVCAR8	NHy3d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPqUYFZOC5yMT2xNFAh\|ryP	Mm\zOFghcA>?		M2nnW2xw\yCJSUWwQU04Njh2IF2=	NFnrd3UzOjN\|NkK0Oi=>
SKOV3	M3T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHvWJpGOC5yMT2xNFAh\|ryP	M2nae\|Q5KGh?		MkDxUI9oKEeLNUC9MVgvPDFiTR?=	M1XkV\|IzOzN4MkS2
RXF631L	M2nVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli0NE4xOS1zMECg{txO	M1K0V\|Q5KGh?		NYr0WoFGVG:pIFfJOVA:NThwMkGgUS=>	NH3pemQzOjN\|NkK0Oi=>
ACHN	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUiwMlAyNTFyMDFOwG0>	M4XwRlQ5KGh?		NFzuOVFNd2diR1m1NF0uPy57NTDN	MoTvNlI{OzZ{NE[=
St-4	NXL6Vlg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnqWmp7OC5yMT2xNFAh\|ryP	NWGzRll3PDhiaB?=		MkHFUI9oKEeLNUC9MVcvPDdiTR?=	NV\JWZFJOjJ\|M{[yOFY>
MKN1	M3LVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DPNVAvODFvMUCwJO69VQ>?	NXjiRmxVPDhiaB?=		NUDqe44{VG:pIFfJOVA:NThwNEGgUS=>	MXGyNlM{PjJ2Nh?=
MKN7	NHLBTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr5cFIxNjBzLUGwNEDPxE1?	MYe0PEBp		NIC2W5lNd2diR1m1NF0uPy54ODDN	MUeyNlM{PjJ2Nh?=
MKN28	NIXmSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYewMlAyNTFyMDFOwG0>	NWSyPWNRPDhiaB?=		M{XaW2xw\yCJSUWwQU04NjB5IF2=	MVGyNlM{PjJ2Nh?=
MKN45	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGwMlAyNTFyMDFOwG0>	NWrzdXBzPDhiaB?=		NUjOWFdjVG:pIFfJOVA:NThwM{SgUS=>	NVzoeINCOjJ\|M{[yOFY>
MKN74	NYnJTFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrUXnUxNjBzLUGwNEDPxE1?	MXG0PEBp		M3;ROmxw\yCJSUWwQU04NjR{IF2=	NETyOm4zOjN\|NkK0Oi=>
DU145	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYToNW85OC5yMT2xNFAh\|ryP	MYq0PEBp		MlXWUI9oKEeLNUC9MVgvOTZiTR?=	M3ftcFIzOzN4MkS2
PC3	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknFNE4xOS1zMECg{txO	MXK0PEBp		NVvxe3ByVG:pIFfJOVA:NThwNk[gUS=>	M3r1blIzOzN4MkS2
Trypanosoma brucei brucei	NWHUXXRzTnWwY4Tpc44hSXO\|YYm=	MUeyNFAhdk1?	MmrFNVIhcA>?	NX:xXo5xTE2VTx?=	MUfE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	NEnWV4kzPDhyNUm0Oi=>
Trypanosoma brucei brucei	M2Dy[GZ2dmO2aX;uJGF{e2G7		M1;wS\|E5KGh?	NHz1OpZFVVOR	MlrnTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	MorzNlQ5ODV7NE[=
Trypanosoma brucei brucei	MmXTSpVv[3Srb36gRZN{[Xl?	MXuyNFAhdk1?	MU[xNkBp	M1T1T2ROW09?	MUXF[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	NWDGeGd7OjR6MEW5OFY>
Trypanosoma brucei brucei	NGP6coZHfW6ldHnvckBCe3OjeR?=	NIHJPJozODBibl2=	NFewfVQyOiCq	NWTtOVI3TE2VTx?=	NI\2N4FG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	NETpdFkzPDhyNUm0Oi=>
UM-UC-3	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTNzNTDwUS=>	NH;m[5hUSU6JRWK=
SBC-1	M1j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7HTWM2OD15NEKgdG0>	MWfTRW5ITVJ?
MKN1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELFRoNKSzVyPUKuPEBvVQ>?	M1zIfnNCVkeHUh?=
NCI-H720	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTNwNUegcm0>	MV;TRW5ITVJ?
BFTC-909	M{DZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjveZRRUUN3ME2zMlcyKG6P	MVjTRW5ITVJ?
BPH-1	NFLMfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\xR2lEPTB;ND63OkBvVQ>?	MXPTRW5ITVJ?
PC-3	NFnPZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfRcFZKSzVyPUWuNFkhdk1?	NGjkcllUSU6JRWK=
AN3-CA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTVwNU[gcm0>	M{\Kc3NCVkeHUh?=
HN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfYVY5TUUN3ME21Mlk3KG6P	MX7TRW5ITVJ?
HCC2218	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfJ[XFZUUN3ME22MlYyKG6P	NX\Sclc2W0GQR1XS
KP-4	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoraTWM2OD15IH7N	MoT6V2FPT0WU
LU-139	NWCxRXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTdwN{egcm0>	MYTTRW5ITVJ?
ETK-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPNTmJKSzVyPUeuPFghdk1?	M33RZ3NCVkeHUh?=
Ramos-2G6-4C10	NV3DRXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRThwNEmgcm0>	MnjpV2FPT0WU
MHH-PREB-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTlwMUKgcm0>	NGnIcVdUSU6JRWK=
DU-4475	NEX6VFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH1XFZYUUN3ME25MlQ1KG6P	M{PRU3NCVkeHUh?=
NCI-H1666	NV7sbod3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzwZ4s6UUN3ME25MlcyKG6P	MUnTRW5ITVJ?
CAMA-1	M{X0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rNV2lEPTB;OT64JI5O	M4TneHNCVkeHUh?=
TYK-nu	NGrEZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPwbJhKSzVyPUmuPVQhdk1?	NIXLZoJUSU6JRWK=
MFE-280	NVrN[pVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTlwOUmgcm0>	Mn\PV2FPT0WU
A549	NV\ifI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW0TWM2OD1zMD6xOEBvVQ>?	MXvTRW5ITVJ?
769-P	M3mxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjXNW5kUUN3ME2xNE41PCCwTR?=	MmrnV2FPT0WU
L-363	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LPRmlEPTB;MUCuOlkhdk1?	MVPTRW5ITVJ?
ES8	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PxZWlEPTB;MUCuPUBvVQ>?	NX3YZYpKW0GQR1XS
PA-1	NFrPc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrUTWM2OD1zMT64NkBvVQ>?	NFf2V4tUSU6JRWK=
Mewo	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTFzLkm5JI5O	MmS1V2FPT0WU
HSC-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPUTWM2OD1zMj6yNUBvVQ>?	NF\UVlZUSU6JRWK=
H4	M{m1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULQNmFvUUN3ME2xNk43PyCwTR?=	NFjlU2RUSU6JRWK=
BB65-RCC	NGDlbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTF{LkeyJI5O	NUTofYdlW0GQR1XS
NCI-H1793	NHjuR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPLTWM2OD1zMj64NkBvVQ>?	NH73VmNUSU6JRWK=
KARPAS-45	NYjtTXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjtSGd{UUN3ME2xN{42OSCwTR?=	M1zjfnNCVkeHUh?=
GCT	NU[0WYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInZSJBKSzVyPUGzMlY5KG6P	NGfsRVhUSU6JRWK=
EoL-1	NVrWem1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TXOGlEPTB;MUOuPVMhdk1?	NWj2SYI5W0GQR1XS
LB2241-RCC	M{HMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF2LkCxJI5O	MlTqV2FPT0WU
ES5	NFP6XVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PicmlEPTB;MUSuO\|Qhdk1?	MWHTRW5ITVJ?
LOXIMVI	M3\Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXJelFKSzVyPUG0Mlk6KG6P	NFizb2lUSU6JRWK=
COR-L105	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPITWM2OD1zNT6wOEBvVQ>?	M2C5T3NCVkeHUh?=
P12-ICHIKAWA	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFO3codKSzVyPUG1MlEhdk1?	NXfjd2w6W0GQR1XS
CHL-1	NFjVcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13LWWlEPTB;MUWuOFUhdk1?	MW\TRW5ITVJ?
VMRC-RCZ	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LGUmlEPTB;MUWuOlMhdk1?	MnvUV2FPT0WU
HH	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF3Lkegcm0>	M1TOZXNCVkeHUh?=
NUGC-3	M1exdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTF4LkO0JI5O	Mn72V2FPT0WU
EGI-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Txd2lEPTB;MU[uOFMhdk1?	MmfzV2FPT0WU
OS-RC-2	NU\FRmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\xdnNKSzVyPUG2MlQ4KG6P	MUjTRW5ITVJ?
MOLT-16	M{iycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGiz[GNKSzVyPUG3MlE2KG6P	MoHFV2FPT0WU
NCI-H209	NYXRXXB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LuWWlEPTB;MUeuNlkhdk1?	M{XKeHNCVkeHUh?=
697	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHqwdmdKSzVyPUG3MlQ{KG6P	NEDvbWNUSU6JRWK=
D-56MG	M1TLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrMTWM2OD1zNz62PUBvVQ>?	NHXXXFhUSU6JRWK=
VA-ES-BJ	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUex[Zo5UUN3ME2xO{45OyCwTR?=	MWrTRW5ITVJ?
EW-16	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\weYpGUUN3ME2xPE4xPCCwTR?=	MWHTRW5ITVJ?
HGC-27	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPINmc5UUN3ME2xPE4xPiCwTR?=	MmOzV2FPT0WU
ES7	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnaeJFpUUN3ME2xPE4xQSCwTR?=	NFH4UmhUSU6JRWK=
HuH-7	NFj6fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPXTWM2OD1zOD60JI5O	Ml\qV2FPT0WU
BCPAP	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTF6Lk[1JI5O	NVv4N2tqW0GQR1XS
SW1710	NEX4W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TWO2lEPTB;MUiuO\|Ihdk1?	MX\TRW5ITVJ?
IST-MEL1	NUXaeFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnvTWM2OD1zOD63O{BvVQ>?	MkPvV2FPT0WU
SF295	NIHpToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3GW2pqUUN3ME2xPE46OyCwTR?=	MoW3V2FPT0WU
RPMI-7951	NUTpV5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVW4dohyUUN3ME2xPU4zQCCwTR?=	NWDDeG14W0GQR1XS
SF126	NFfoendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTteYVvUUN3ME2xPU41OSCwTR?=	MY\TRW5ITVJ?
GAMG	NEW5ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXVNnRKSzVyPUG5MlQ5KG6P	MXvTRW5ITVJ?
KNS-81-FD	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn6UG1KSzVyPUG5MlU1KG6P	NXu0W4F{W0GQR1XS
RT-112	NUTqVpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGj0dJNKSzVyPUG5MlY3KG6P	NX[wbGF7W0GQR1XS
DEL	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHSTWM2OD1{MD60PUBvVQ>?	NUjjPVhnW0GQR1XS
CGTH-W-1	M1PV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PFTmlEPTB;MkCuOlMhdk1?	M32zd3NCVkeHUh?=
HOS	NEfMSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Ww[WlEPTB;MkGuNFYhdk1?	MoXCV2FPT0WU
ES4	NHHkXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjrU3ozUUN3ME2yNU4xQCCwTR?=	M{js[XNCVkeHUh?=
RXF393	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJzLkS1JI5O	NE\2SHJUSU6JRWK=
NCI-H2030	M4HM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTTblVKSzVyPUKxMlUzKG6P	M2eyOHNCVkeHUh?=
YH-13	NUTUUI9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJzLki4JI5O	MXvTRW5ITVJ?
HT-1080	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjFZ2ZkUUN3ME2yNU46OyCwTR?=	NXizVm5kW0GQR1XS
NCI-SNU-1	NGDiNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJzLkm1JI5O	M4XFZnNCVkeHUh?=
G-402	NUjaNXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLFO3hKSzVyPUKyMlE3KG6P	MXvTRW5ITVJ?
786-0	NE\EcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJ{LkK5JI5O	M2S4TnNCVkeHUh?=
ME-180	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:0TWM2OD1{Mj60N{BvVQ>?	MWTTRW5ITVJ?
NB69	M3LCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Tm[GlEPTB;MkKuOVMhdk1?	M4fUOHNCVkeHUh?=
J-RT3-T3-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvlTWM2OD1{Mj65OkBvVQ>?	MnzkV2FPT0WU
TGBC1TKB	NY\oT4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1m1TGlEPTB;MkOuNFUhdk1?	MnLiV2FPT0WU
SW780	NXPQXpJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT1TWM2OD1{Mz6xN{BvVQ>?	MoX4V2FPT0WU
MG-63	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPWfGlKSzVyPUKzMlQ2KG6P	MVXTRW5ITVJ?
BV-173	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTJ\|Lki3JI5O	M2mxbnNCVkeHUh?=
CAL-51	M4f1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHueFBKSzVyPUKzMlg6KG6P	MoizV2FPT0WU
A375	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3sTWM2OD1{Mz65N{BvVQ>?	Ml3YV2FPT0WU
MEL-HO	M4e5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVuzNVdmUUN3ME2yOE4xPCCwTR?=	M{DpR3NCVkeHUh?=
EFO-27	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NICzUoxKSzVyPUK0MlM{KG6P	NXrnVFdTW0GQR1XS
Hs-578-T	NUXEZ5lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTtTWM2OD1{ND61PEBvVQ>?	NFTnNppUSU6JRWK=
NBsusSR	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVP1NWUyUUN3ME2yOE43KG6P	MUXTRW5ITVJ?
CTB-1	NHP5fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\RWpBKSzVyPUK0MlY4KG6P	Mn\nV2FPT0WU
FTC-133	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJ3LkGgcm0>	MmizV2FPT0WU
MOLT-4	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTBTWM2OD1{NT6xNkBvVQ>?	MoLnV2FPT0WU
HO-1-N-1	NWrZZ2dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDWOnFKSzVyPUK1MlE2KG6P	NIS2ZVhUSU6JRWK=
ES3	NUTWPGFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTJ3LkKyJI5O	MnjXV2FPT0WU
TI-73	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3ae4lLUUN3ME2yOU4zQCCwTR?=	MYrTRW5ITVJ?
MPP-89	NVjw[ZRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ3LkOyJI5O	NV\iNG5HW0GQR1XS
KYSE-150	M4C4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfaOFNKSzVyPUK1Mlg6KG6P	M3n4cnNCVkeHUh?=
LXF-289	NHHDbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJ4LkC0JI5O	NIPPSIRUSU6JRWK=
SK-LU-1	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfFNmhKSzVyPUK2MlE4KG6P	MlLtV2FPT0WU
HOP-92	NWDGZYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLTTWM2OD1{Nj60PEBvVQ>?	NXrKemVvW0GQR1XS
HuO9	M1SyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jlNWlEPTB;Mk[uO\|Yhdk1?	NVTuWGI{W0GQR1XS
SW962	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\xTWM2OD1{Nj63OkBvVQ>?	MoP4V2FPT0WU
RS4-11	NHiwSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHKwTohKSzVyPUK2MlkyKG6P	MUXTRW5ITVJ?
NCI-H292	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nzUWlEPTB;Mkegcm0>	M3fud3NCVkeHUh?=
DB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJ5LkO2JI5O	M3TlVXNCVkeHUh?=
SW1088	M4jZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfXTWM2OD1{OD6yPUBvVQ>?	MlzCV2FPT0WU
A204	NXzvR2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ6LkS3JI5O	MWDTRW5ITVJ?
A3-KAW	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz1[INoUUN3ME2yPE43PCCwTR?=	Ml\zV2FPT0WU
MV-4-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfQUnNKUUN3ME2yPE44KG6P	MnvmV2FPT0WU
ES1	M1nXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC3TWM2OD1{OD64OEBvVQ>?	MmrUV2FPT0WU
ONS-76	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXW0T20{UUN3ME2yPU4xPSCwTR?=	MUTTRW5ITVJ?
D-263MG	NFn4SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzjc3d5UUN3ME2yPU4{PSCwTR?=	Ml\DV2FPT0WU
U-2-OS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJ7LkWgcm0>	M{niT3NCVkeHUh?=
T98G	NUDTeJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXRSpViUUN3ME2yPU45QCCwTR?=	NHrFb3ZUSU6JRWK=
GI-ME-N	NVrCZnFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1roTGlEPTB;MkmuPVEhdk1?	Mn7uV2FPT0WU
BHT-101	NILUV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTNyLkC1JI5O	MkXUV2FPT0WU
NOS-1	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fwUWlEPTB;M{CuNVIhdk1?	NYfVboFtW0GQR1XS
AsPC-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITVTZdKSzVyPUOwMlIhdk1?	MkDKV2FPT0WU
QIMR-WIL	NV;r[nF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3m2fGlEPTB;M{CuOkBvVQ>?	M{LkbXNCVkeHUh?=
JVM-3	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;0PXZKSzVyPUOwMlg{KG6P	MmTtV2FPT0WU
KU-19-19	NU\3SZlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fpT2lEPTB;M{GuNVMhdk1?	NXfHZo9tW0GQR1XS
OVCAR-8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTNzLkK2JI5O	M4Dn[3NCVkeHUh?=
BEN	NF3UblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XKeWlEPTB;M{GuOlMhdk1?	NWjPbZRzW0GQR1XS
BE-13	NXSydFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPhUnNbUUN3ME2zNU45OiCwTR?=	NHizbYVUSU6JRWK=
EW-18	NWDYSGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7tfJlZUUN3ME2zNU45PiCwTR?=	MVzTRW5ITVJ?
ECC10	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH6TWM2OD1\|MT65OUBvVQ>?	NU\qcZF1W0GQR1XS
CTV-1	M3;pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTN{LkiyJI5O	NUSwTmplW0GQR1XS
COLO-800	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrEVWh{UUN3ME2zNk46OiCwTR?=	MU\TRW5ITVJ?
A2058	NFm5XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjhT3lSUUN3ME2zN{4zPSCwTR?=	MoPrV2FPT0WU
VM-CUB-1	M{exNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvoOIREUUN3ME2zN{41OyCwTR?=	NU[2WXlbW0GQR1XS
Ca9-22	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofUTWM2OD1\|Mz61OUBvVQ>?	M1e4PXNCVkeHUh?=
COLO-684	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n1TGlEPTB;M{OuOVghdk1?	M4TWVnNCVkeHUh?=
RPMI-8226	NYLFV3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTN\|LkiyJI5O	NWrveYx4W0GQR1XS
SK-NEP-1	NWG1OpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP5PJhTUUN3ME2zOE4yPSCwTR?=	MXHTRW5ITVJ?
Becker	NVPjVm42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PFb2lEPTB;M{SuNlEhdk1?	MmTIV2FPT0WU
NCI-H28	NWSxNWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN2LkS0JI5O	NWDsU2pOW0GQR1XS
CAL-120	M1jSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPDVHZ3UUN3ME2zOE44OiCwTR?=	NYXPR4pkW0GQR1XS
MDA-MB-157	NXPuXItbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rJTGlEPTB;M{WuOFEhdk1?	M3jTOnNCVkeHUh?=
OVCAR-5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTN3LkS3JI5O	NVTk[3JwW0GQR1XS
LAMA-84	M3HST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOxfnFWUUN3ME2zOU45PyCwTR?=	MYXTRW5ITVJ?
CAKI-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\rXWlEPTB;M{[uOFMhdk1?	NGDhdHFUSU6JRWK=
Daoy	NYTpcXNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTN4Lkegcm0>	M4XMZXNCVkeHUh?=
CAL-62	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELmTG9KSzVyPUO2Mlg3KG6P	NFixbmVUSU6JRWK=
8-MG-BA	Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf0fnlvUUN3ME2zO{4zPSCwTR?=	NF3HNohUSU6JRWK=
8505C	NHzTRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O2fmlEPTB;M{euOVEhdk1?	NVH3e25LW0GQR1XS
LNCaP-Clone-FGC	NUfNVHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN5LkW5JI5O	NVnnR\|RCW0GQR1XS
CAL-39	NFXTSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnOyTWM2OD1\|Nz65JI5O	Ml3FV2FPT0WU
MN-60	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHpTWM2OD1\|Nz65OkBvVQ>?	NWj1SINMW0GQR1XS
RKO	M3zMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfRdmpKSzVyPUO4MlM{KG6P	M4XzUXNCVkeHUh?=
U251	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTN6LkSzJI5O	MmH1V2FPT0WU
SJSA-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknSTWM2OD1\|OD61OEBvVQ>?	NEXBRmtUSU6JRWK=
CAL-12T	M2T3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGO1PXNKSzVyPUO4MlYhdk1?	NHLONXFUSU6JRWK=
HCC1419	NFnUTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\5TWM2OD1\|OD63NUBvVQ>?	NUSwRWoxW0GQR1XS
CO-314	NIHNboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTN6Lke0JI5O	MUDTRW5ITVJ?
LB1047-RCC	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vqUmlEPTB;M{iuPFEhdk1?	NVK0NXRuW0GQR1XS
A101D	M{PYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fWb2lEPTB;M{iuPVchdk1?	MYrTRW5ITVJ?
MDA-MB-175-VII	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPITWM2OD1\|OT61NUBvVQ>?	MVXTRW5ITVJ?
MZ2-MEL	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;JTWM2OD1\|OT62OkBvVQ>?	MUfTRW5ITVJ?
NB5	NUPOOFZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHTSGtKSzVyPUSwMlY1KG6P	NX;US3UzW0GQR1XS
G-401	M1LBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LXUmlEPTB;NECuPFIhdk1?	NWfjWGd{W0GQR1XS
HT	NHe0VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS2TWM2OD12MT6wNkBvVQ>?	M1LhXHNCVkeHUh?=
8305C	NYD1Z\|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIi0OGpKSzVyPUSxMlg4KG6P	M2fqNXNCVkeHUh?=
BHY	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUeyTXN3UUN3ME20Nk44OiCwTR?=	NYn6e5BZW0GQR1XS
NTERA-S-cl-D1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrQT3d3UUN3ME20N{BvVQ>?	MYLTRW5ITVJ?
T-24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR\|LkizJI5O	M1TT[3NCVkeHUh?=
EPLC-272H	NIjjTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTLdZRFUUN3ME20OE4{QSCwTR?=	NYXOPY9PW0GQR1XS
PSN1	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PQVGlEPTB;NESuOEBvVQ>?	MYjTRW5ITVJ?
NCI-H2452	NVfRXZA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTR2LkW4JI5O	NEDWW\|BUSU6JRWK=
KS-1	NIjLNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlexTWM2OD12ND62OkBvVQ>?	MkjHV2FPT0WU
HD-MY-Z	NX3nbngxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvMbJFKSzVyPUS0MlkzKG6P	MYDTRW5ITVJ?
KNS-62	M13oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXaW2NKSzVyPUS1MlM5KG6P	NF\jc2dUSU6JRWK=
NOMO-1	M1q5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInwOY9KSzVyPUS1Mlg4KG6P	MoD0V2FPT0WU
SK-HEP-1	NEH4WZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\5NpZKSzVyPUS2MlA1KG6P	NGn6OIlUSU6JRWK=
IGR-1	NYHIeo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzVOYRKSzVyPUS2MlE{KG6P	MWDTRW5ITVJ?
KYSE-180	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTC[JBWUUN3ME20Ok4yPyCwTR?=	MXPTRW5ITVJ?
EW-22	NVfBW5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnCcopNUUN3ME20Ok4zKG6P	MnrEV2FPT0WU
NCI-H1355	NXLZdlgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTR4LkO0JI5O	M3HSWHNCVkeHUh?=
DOHH-2	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1n0UGlEPTB;NE[uN\|chdk1?	M{Dz[HNCVkeHUh?=
A4-Fuk	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTR4LkWyJI5O	MVrTRW5ITVJ?
PC-14	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXuzO3JDUUN3ME20Ok42PyCwTR?=	NEPLXm9USU6JRWK=
TE-5	NYTIVmZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\xVmlEPTB;NE[uPFQhdk1?	NVnPPXR5W0GQR1XS
LB996-RCC	NXX5fZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTR5LkG5JI5O	NF\BUYJUSU6JRWK=
NCI-H1623	NYXmTYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojUTWM2OD12Nz63OkBvVQ>?	MmruV2FPT0WU
NCI-H1155	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTR6LkOyJI5O	M4X4eHNCVkeHUh?=
LoVo	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPNO5NoUUN3ME20PE41KG6P	NX7kbXl[W0GQR1XS
MCF7	NFO3O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjXTWM2OD12OD61PEBvVQ>?	MoPsV2FPT0WU
AGS	M2n5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;CblZKSzVyPUS4Mlc4KG6P	MX\TRW5ITVJ?
PFSK-1	NULTXIc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTR7LkC2JI5O	M{TVSnNCVkeHUh?=
22RV1	M2Pm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLaTWM2OD12OT6wPUBvVQ>?	NHPpdo9USU6JRWK=
COR-L23	M2mxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHnTWM2OD12OT6xOkBvVQ>?	MXnTRW5ITVJ?
D-283MED	M1n0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DzTWlEPTB;NEmuOlEhdk1?	NHHYZZJUSU6JRWK=
SW982	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HCU2lEPTB;NEmuPVEhdk1?	MYHTRW5ITVJ?
SW620	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPNN3pKSzVyPUWwMlM3KG6P	M4ruZXNCVkeHUh?=
KYSE-140	NGnXb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrpSoFKSzVyPUWwMlU2KG6P	MYfTRW5ITVJ?
GCIY	NWjONJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHTOI4{UUN3ME21NE43PyCwTR?=	NGLMXFJUSU6JRWK=
MHH-ESS-1	NFPibGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTVzLkm1JI5O	MWrTRW5ITVJ?
D-423MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;ycotRUUN3ME21Nk4xQCCwTR?=	MX3TRW5ITVJ?
SF539	NXP1SnluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTV{LkO1JI5O	MUjTRW5ITVJ?
RPMI-2650	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvPXIhDUUN3ME21Nk43QSCwTR?=	M2XJU3NCVkeHUh?=
GR-ST	M1jFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnKwTWM2OD13Mj64O{BvVQ>?	NHLHS3ZUSU6JRWK=
YKG-1	NWrIXmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmq0TWM2OD13MzDuUS=>	M2rzc3NCVkeHUh?=
SK-MES-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILJbGZKSzVyPUWzMlI3KG6P	M{e1d3NCVkeHUh?=
HLE	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fjcmlEPTB;NUOuOFchdk1?	MYTTRW5ITVJ?
RVH-421	NUHTcpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LodWlEPTB;NUOuOlchdk1?	NVXjR2FMW0GQR1XS
C32	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\JS2lEPTB;NUOuPFMhdk1?	NFHXOohUSU6JRWK=
GB-1	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TzSWlEPTB;NUSuNkBvVQ>?	MWnTRW5ITVJ?
SNB75	NGTuWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXCU29lUUN3ME21OE4zPiCwTR?=	NXe0NHpoW0GQR1XS
EM-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLJSFM{UUN3ME21OE41KG6P	MmDZV2FPT0WU
RH-1	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHSTWM2OD13ND63JI5O	NIXoT4VUSU6JRWK=
NKM-1	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTPTWM2OD13ND64NUBvVQ>?	MXnTRW5ITVJ?
NCI-H2405	NHPaVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy4O3JKSzVyPUW0Mlg5KG6P	MV;TRW5ITVJ?
KYSE-450	M3;MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rvdWlEPTB;NUWuNVYhdk1?	NUfibZF3W0GQR1XS
A704	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj1TWM2OD13NT61PUBvVQ>?	NY\IfG9yW0GQR1XS
HAL-01	M17uV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLRdHRKSzVyPUW1Mlg{KG6P	NInLUZhUSU6JRWK=
TE-11	M{T5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvXWXVKSzVyPUW1Mlk6KG6P	NXn0[5Z7W0GQR1XS
DOK	NEHkT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PTZmlEPTB;NU[uNFIhdk1?	NH3HZm1USU6JRWK=
KY821	M1HveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTV4LkKgcm0>	MnywV2FPT0WU
KGN	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjoZ2hwUUN3ME21Ok4{OiCwTR?=	M4rBN3NCVkeHUh?=
MC116	NEjYXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUf5NWdIUUN3ME21O{45KG6P	MnzyV2FPT0WU
PANC-08-13	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTV6LkCxJI5O	MVrTRW5ITVJ?
KE-37	M2O3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf2OVZKSzVyPUW4Mlc4KG6P	MYLTRW5ITVJ?
KYSE-410	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2m5OWlEPTB;NUmuOFchdk1?	NVr0[WNXW0GQR1XS
RO82-W-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzRWGJKSzVyPUW5Mlkhdk1?	MUfTRW5ITVJ?
M14	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELYOXFKSzVyPU[wMlA1KG6P	NHrmfJBUSU6JRWK=
GI-1	M2TCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIOy[3BKSzVyPU[wMlMhdk1?	NWjEU\|d3W0GQR1XS
ML-2	NWK4RYxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULTOohGUUN3ME22NE43OiCwTR?=	M3TvWXNCVkeHUh?=
BFTC-905	NYfTOGFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW5O\|gzUUN3ME22NE43PSCwTR?=	M3LKfXNCVkeHUh?=
DMS-273	NHHT[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjhZVRuUUN3ME22NE45PyCwTR?=	Mmf1V2FPT0WU
MDA-MB-361	NV\me4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTZzIH7N	MljiV2FPT0WU
MSTO-211H	NXzVS4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LacWlEPTB;NkOuOVEhdk1?	MXrTRW5ITVJ?
MEG-01	M{PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHixfpBKSzVyPU[zMlUzKG6P	NGXpfHlUSU6JRWK=
M059J	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZ\|LkW4JI5O	MUXTRW5ITVJ?
LN-405	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O1U2lEPTB;NkOuPFUhdk1?	NVHZRXE2W0GQR1XS
NCI-H1581	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:4TWM2OD14ND6wN{BvVQ>?	Mnz1V2FPT0WU
TCCSUP	NGTkWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHHTWM2OD14ND61N{BvVQ>?	Mli4V2FPT0WU
SW872	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLuTWM2OD14ND61O{BvVQ>?	MYHTRW5ITVJ?
KYSE-510	NYHWOFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTZ3Lke1JI5O	NVjnZ2pmW0GQR1XS
NCI-H1792	NVnLNW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXwW45xUUN3ME22Ok4yPSCwTR?=	MlHNV2FPT0WU
SW13	M4LXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLh[pBKSzVyPU[2MlUhdk1?	MkOyV2FPT0WU
TE-8	NYrmbYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDVb5JYUUN3ME22Ok42OiCwTR?=	M2mzTnNCVkeHUh?=
SCH	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3HTWM2OD14Nz6xJI5O	MYTTRW5ITVJ?
NEC8	NYX2VpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTZ5LkK0JI5O	M4PIRnNCVkeHUh?=
HuO-3N1	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfVbGluUUN3ME22O{4{OSCwTR?=	Mo\3V2FPT0WU
EFM-19	NX3FPJdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXhTWM2OD14Nz61JI5O	MXrTRW5ITVJ?
HEC-1	NXT4cZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYKxOpZnUUN3ME22O{42OiCwTR?=	NYjJfFRrW0GQR1XS
T47D	NYCyemFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrl[mxKSzVyPU[3Mlg4KG6P	MnuzV2FPT0WU
SNU-423	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXIdZZKSzVyPU[3Mlk5KG6P	NFvyNI9USU6JRWK=
WM-115	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGKxS2VKSzVyPU[4MlE1KG6P	MVzTRW5ITVJ?
CaR-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHwNJlKSzVyPU[4MlI2KG6P	MXfTRW5ITVJ?
KU812	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnaUJpKSzVyPU[4MlY6KG6P	NWSyOIdLW0GQR1XS
AM-38	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDIXVNCUUN3ME22PU4{OSCwTR?=	NFT1eJNUSU6JRWK=
KOSC-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHKO4lKSzVyPU[5Mlk4KG6P	MoT3V2FPT0WU
MC-IXC	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTdyLkC4JI5O	NW[3flFVW0GQR1XS
SCC-4	NX[yenlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnEPVVKSzVyPUexMlM5KG6P	NFrCN3dUSU6JRWK=
Calu-3	NV;TSXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmj1TWM2OD15MT65PEBvVQ>?	MXTTRW5ITVJ?
RPMI-8866	NFTBdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTd{LkiyJI5O	MlHSV2FPT0WU
OVCAR-4	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXVbmJOUUN3ME23N{4{PiCwTR?=	MVvTRW5ITVJ?
OAW-42	M3GwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTd\|LkO5JI5O	MX3TRW5ITVJ?
ATN-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTd\|Lki3JI5O	MVXTRW5ITVJ?
CHP-212	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jkN2lEPTB;N{SuPVUhdk1?	MkKwV2FPT0WU
C2BBe1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nVUGlEPTB;N{WuNFMhdk1?	NHvjVHRUSU6JRWK=
A498	M4r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUX6WoZqUUN3ME23OU4yPSCwTR?=	NGXlRotUSU6JRWK=
SH-4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TzcGlEPTB;N{WuNlEhdk1?	MXHTRW5ITVJ?
SNU-449	NWjuSGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTd3Lke5JI5O	M{e5[HNCVkeHUh?=
RD	NV:4UJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TvVWlEPTB;N{WuPFYhdk1?	MU\TRW5ITVJ?
PANC-03-27	NHe4T4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHZ[IZKSzVyPUe2MlI2KG6P	MYPTRW5ITVJ?
S-117	NFn2RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVW1VY4zUUN3ME23Ok4zPyCwTR?=	NVHTV3N7W0GQR1XS
SK-MEL-2	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkmzTWM2OD15Nj63OUBvVQ>?	NHvPZ2dUSU6JRWK=
LK-2	M4PvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXT1eGFlUUN3ME23O{4xPSCwTR?=	NIW2XmtUSU6JRWK=
CP50-MEL-B	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUT6TXJRUUN3ME23O{41KG6P	Mke5V2FPT0WU
647-V	NHS0bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zrN2lEPTB;N{iuNFchdk1?	M{LqUHNCVkeHUh?=
LU-134-A	NFTwbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPvTWM2OD15OT6wN{BvVQ>?	MXrTRW5ITVJ?
5637	NH\0V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYX2[45rUUN3ME23PU4zOyCwTR?=	Mne2V2FPT0WU
NCI-H1437	M1q2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTHUHNKSzVyPUiwMlUhdk1?	MYnTRW5ITVJ?
NCI-H460	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRThzLkKzJI5O	MV7TRW5ITVJ?
BxPC-3	M331dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\NSFY1UUN3ME24NU41PiCwTR?=	MWTTRW5ITVJ?
CAN	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInrd\|ZKSzVyPUixMlg1KG6P	NUPqXlg{W0GQR1XS
KINGS-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7zN\|JKSzVyPUiyMlMzKG6P	M1K4SHNCVkeHUh?=
OCUB-M	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DSVGlEPTB;OEKuOFEhdk1?	MnS4V2FPT0WU
KALS-1	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPSbHhWUUN3ME24Nk42PCCwTR?=	M3HlXnNCVkeHUh?=
OCI-AML2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULj[ml7UUN3ME24Nk43OSCwTR?=	MVvTRW5ITVJ?
A253	M1vOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzsTWM2OD16Mj62OUBvVQ>?	MVjTRW5ITVJ?
LCLC-97TM1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r5bmlEPTB;OEKuPFYhdk1?	Mki1V2FPT0WU
NCI-H520	M1zMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTRUlJKSzVyPUizMlA3KG6P	NHrqO2xUSU6JRWK=
P30-OHK	NW[zRoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHZdpFrUUN3ME24N{42KG6P	NGK5eYpUSU6JRWK=
SBC-5	NGTWdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXyTWM2OD16Mz61NkBvVQ>?	NU\0[nhzW0GQR1XS
HCE-T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\lWpRKSzVyPUizMlc1KG6P	M{jHSHNCVkeHUh?=
JEG-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrv[YdiUUN3ME24OE4yKG6P	MUnTRW5ITVJ?
KG-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zXTWlEPTB;OESuNlQhdk1?	MX3TRW5ITVJ?
MIA-PaCa-2	M2nDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXsTWM2OD16ND61OEBvVQ>?	NGHCNmNUSU6JRWK=
CAL-33	M1HRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nCT2lEPTB;OEWuNFghdk1?	NH3lTVFUSU6JRWK=
639-V	M4LHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L1PWlEPTB;OEWuOFIhdk1?	NWHm[mV7W0GQR1XS
NCI-H1048	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnzTXlKSzVyPUi2MlMyKG6P	M3:0fXNCVkeHUh?=
NCI-H1573	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:0O5dKSzVyPUi3MlQ5KG6P	M3XWOXNCVkeHUh?=
NCI-H2228	M4PyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGraWXNKSzVyPUi4MlI3KG6P	NGTYcHFUSU6JRWK=
NB14	NUW1RYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTh6LkOgcm0>	NHXSeGtUSU6JRWK=
SCC-25	M3nhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfmeWE2UUN3ME24PU45OiCwTR?=	MXvTRW5ITVJ?
A431	NVHsZopNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLzc2RKSzVyPUi5Mlk4KG6P	NHXkPZFUSU6JRWK=
SN12C	NEKwc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjHOWNDUUN3ME25NE43OiCwTR?=	NIfNdYZUSU6JRWK=
HuCCT1	NUn2cGIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;LVHFwUUN3ME25NE44PiCwTR?=	MnLBV2FPT0WU
LS-123	NGXoSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf2c\|BsUUN3ME25Nk4yQCCwTR?=	M1jVSHNCVkeHUh?=
CAL-85-1	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTl{LkS4JI5O	MnHEV2FPT0WU
ES6	M2fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnBO4dzUUN3ME25Nk45OyCwTR?=	Ml7WV2FPT0WU
NCI-H650	M2LSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTl2LkC5JI5O	MkG1V2FPT0WU
NCI-H446	M13Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\wSGlEPTB;OUWuNVIhdk1?	M2L0VXNCVkeHUh?=
EW-13	NHK4VZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjYNFIzUUN3ME25OU44PSCwTR?=	NELneIVUSU6JRWK=
HSC-2	M2m4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvSO41KSzVyPUm1Mlg6KG6P	M1;JXnNCVkeHUh?=
U031	NXX2cWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DCNWlEPTB;OU[uO\|Mhdk1?	MorYV2FPT0WU
EW-11	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mne3TWM2OD17Nj64PEBvVQ>?	NWnM[HdMW0GQR1XS
GAK	NFjsTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\4XGpKSzVyPUm4Mlk{KG6P	NEO2bZpUSU6JRWK=
SK-OV-3	NEDwfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3yPHJoUUN3ME2xNFAvODdibl2=	NF7hcnBUSU6JRWK=
OMC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPwTWM2OD1zMECuNVghdk1?	MUfTRW5ITVJ?
TK10	M1T5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjJTWM2OD1zMECuNlEhdk1?	M3\Rd3NCVkeHUh?=
EKVX	M3Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LX[WlEPTB;MUCwMlYhdk1?	NV7iN2N7W0GQR1XS
Detroit562	NITaUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Dk[2lEPTB;MUCyMlE4KG6P	NWqyb4l5W0GQR1XS
SF268	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXX[YlXUUN3ME2xNFIvOzRibl2=	MX7TRW5ITVJ?
SNU-387	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPRTWM2OD1zMESuNVchdk1?	NWDO[\|VnW0GQR1XS
MDA-MB-231	NUPocmppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\mdnNbUUN3ME2xNFUvODZibl2=	NYXwUXVQW0GQR1XS
NCI-H1563	M2f4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIH0dpZKSzVyPUGwOU4yQCCwTR?=	MUTTRW5ITVJ?
D-502MG	M37G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XORmlEPTB;MUC1Mlchdk1?	NGL2RWZUSU6JRWK=
A2780	NFTDT\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfCc21XUUN3ME2xNFYvPDdibl2=	MmTqV2FPT0WU
IA-LM	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTFyNz61NUBvVQ>?	M3;lfXNCVkeHUh?=
D-392MG	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjsbnNKSzVyPUGwO{42PCCwTR?=	MnXNV2FPT0WU
MS-1	NYi2N2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3OzTGlEPTB;MUC3MlcyKG6P	NF7uS3dUSU6JRWK=
SW1990	MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTFyOD61OEBvVQ>?	NFL4Z3RUSU6JRWK=
HEL	M1Xz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLXSI8zUUN3ME2xNFkvOjlibl2=	M3;aeHNCVkeHUh?=
SW1573	NHvIVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUS0TY9tUUN3ME2xNFkvOzFibl2=	MV3TRW5ITVJ?
SW1783	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFzMD6yNkBvVQ>?	MX\TRW5ITVJ?
COLO-680N	NHvPUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTyN4RKSzVyPUGxNE44PiCwTR?=	MlrRV2FPT0WU
NCI-N87	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PaPGlEPTB;MUGxMlA1KG6P	NFPuVYZUSU6JRWK=
SK-MEL-28	M2fITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrFTpd7UUN3ME2xNVEvPTVibl2=	MmD1V2FPT0WU
BT-20	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Dr[mlEPTB;MUGyMlAyKG6P	NF20OlBUSU6JRWK=
NCI-H1648	M1i3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXSOIdyUUN3ME2xNVMhdk1?	M{HlNnNCVkeHUh?=
no-11	NXroVZdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFzMz6yPEBvVQ>?	M2Cz[nNCVkeHUh?=
MOLT-13	NWXvS4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LzXWlEPTB;MUGzMlQ1KG6P	MYPTRW5ITVJ?
NCI-H2170	NF60VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYOxNZhvUUN3ME2xNVQvPTFibl2=	NVLqPGxTW0GQR1XS
HTC-C3	NYPSWIZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\pVpFKSzVyPUGxOk45PSCwTR?=	NHjhOXBUSU6JRWK=
LU-99A	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrzeWNDUUN3ME2xNVcvOjFibl2=	MlvGV2FPT0WU
HCC2998	NYjacFBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvDTWM2OD1zMUeuPVIhdk1?	MVfTRW5ITVJ?
NB13	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXEd5BmUUN3ME2xNVcvQTlibl2=	MoTaV2FPT0WU
GT3TKB	NGDifYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH1TWM2OD1zMUiuNFghdk1?	NGrjdXJUSU6JRWK=
BT-549	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFzOD65OUBvVQ>?	M1ztfHNCVkeHUh?=
NCI-H747	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:2TWM2OD1zMUmuN\|Qhdk1?	NXLVd25[W0GQR1XS
EW-1	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXnTWM2OD1zMkCuNkBvVQ>?	M3LIPXNCVkeHUh?=
LB831-BLC	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITlbFNKSzVyPUGyNE43OyCwTR?=	M2\we3NCVkeHUh?=
NMC-G1	M{fYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnUNY1KSzVyPUGyNU4yOSCwTR?=	Mln6V2FPT0WU
COLO-679	NYXq[3ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjYb\|NqUUN3ME2xNlIvOTVibl2=	MVjTRW5ITVJ?
HL-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;uT4dKSzVyPUGyN{4yKG6P	Mke3V2FPT0WU
MKN7	NFHWdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fCVWlEPTB;MUKzMlg{KG6P	NF35R49USU6JRWK=
RERF-LC-MS	NWHzeVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\Kd2lEPTB;MUK0MlMyKG6P	M{LzSnNCVkeHUh?=
DMS-114	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTWXWJJUUN3ME2xNlUvODlibl2=	M{LlZXNCVkeHUh?=
HuP-T4	NFLjO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvmWWdQUUN3ME2xNlYvQTdibl2=	MXvTRW5ITVJ?
HCC2157	NEnzZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF60O3pKSzVyPUGyO{42KG6P	M3;RW3NCVkeHUh?=
SKG-IIIa	NED6SWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDMTWM2OD1zMkiuPEBvVQ>?	MoLWV2FPT0WU
HCT-116	NV;lUGpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTF\|MD62OEBvVQ>?	NVHrO41{W0GQR1XS
BB30-HNC	M4DKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTF\|MD63PEBvVQ>?	NYe2WpV{W0GQR1XS
KYSE-270	NE\Te\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnWTWM2OD1zM{CuPFghdk1?	NHu0Vm9USU6JRWK=
MFM-223	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF\|MT61NUBvVQ>?	M3L0XXNCVkeHUh?=
NH-12	NUDmSWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTlNY46UUN3ME2xN\|IvQTlibl2=	MmPKV2FPT0WU
U-118-MG	M2r1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrZfXBKSzVyPUGzN{43OiCwTR?=	MWfTRW5ITVJ?
ESS-1	NI\mcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTF\|NT6xPEBvVQ>?	NF;ye2xUSU6JRWK=
D-247MG	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDkTWM2OD1zM{WuNlEhdk1?	M1zTSnNCVkeHUh?=
IGROV-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nHeGlEPTB;MUO1Mlc3KG6P	NF\zVFlUSU6JRWK=
C-33-A	M{PDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXxS5dFUUN3ME2xN\|UvQTdibl2=	MYDTRW5ITVJ?
NCI-H1693	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonCTWM2OD1zM{[uNVIhdk1?	M4rXPXNCVkeHUh?=
MLMA	NWLWfZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NViwbHp[UUN3ME2xN\|YvPThibl2=	MmC0V2FPT0WU
SK-N-AS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjEOnp3UUN3ME2xN\|cvOTdibl2=	M2DXS3NCVkeHUh?=
NCI-H1755	M3TGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zGe2lEPTB;MUO4Mlg2KG6P	NWG1[\|RrW0GQR1XS
CHP-134	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\pcIJKSzVyPUGzPU42PSCwTR?=	NI\mXHlUSU6JRWK=
LS-513	NHfydoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljqTWM2OD1zNECuPVEheE1?	NWjMRWlbW0GQR1XS
TE-12	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zXdWlEPTB;MUSwMlk{KG6P	MWHTRW5ITVJ?
KNS-42	M2PiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHOc2d6UUN3ME2xOFQvOyCwTR?=	MlzDV2FPT0WU
SJRH30	M374[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PnUGlEPTB;MUS0MlQ1KG6P	M4r6dHNCVkeHUh?=
NCI-H1092	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHyzc5NKSzVyPUG0OE42OiCwTR?=	MYnTRW5ITVJ?
H-EMC-SS	NXTTN\|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnrTWM2OD1zNE[uPFEhdk1?	NXz1OXR[W0GQR1XS
SK-MEL-3	NH3nZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPoSYJ[UUN3ME2xOFcvPTVibl2=	NI\HWmNUSU6JRWK=
SK-N-FI	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFqxbHZKSzVyPUG0O{42QSCwTR?=	MYrTRW5ITVJ?
NCI-H2126	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHuTWM2OD1zNEiuNVUhdk1?	MkjCV2FPT0WU
NCI-H1299	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\YTWM2OD1zNUCuNlIhdk1?	M1noVnNCVkeHUh?=
CFPAC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF3MD62OkBvVQ>?	MVvTRW5ITVJ?
NCI-H661	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWr0N3JbUUN3ME2xOVEvOjZibl2=	NWXFVpE3W0GQR1XS
KYSE-70	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXoUG1KSzVyPUG1NU44QSCwTR?=	M1K0OnNCVkeHUh?=
SW900	M2i0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTF3ND62OUBvVQ>?	NVzBRVRRW0GQR1XS
Ca-Ski	NIfiRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTF3Nj6zPUBvVQ>?	MlPsV2FPT0WU
HPAF-II	NV;Jc\|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHpcXdPUUN3ME2xOVYvPDdibl2=	M3rLVHNCVkeHUh?=
LB2518-MEL	NFP4bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:zTWM2OD1zNUeuNUBvVQ>?	M1TBeHNCVkeHUh?=
LC-2-ad	NXLKflQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLwTWM2OD1zNUiuOlIhdk1?	NV3xZVA{W0GQR1XS
HCC1806	NIrLU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWxO2NVUUN3ME2xOlcvQDhibl2=	NUDRcG1bW0GQR1XS
UACC-62	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\4ZpU6UUN3ME2xOlgvODlibl2=	MlTFV2FPT0WU
KM-H2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF5MD61PEBvVQ>?	NHzyOFVUSU6JRWK=
NCI-H2347	NF7oTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTF5Mj63NkBvVQ>?	NITjZ\|VUSU6JRWK=
SCC-15	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGmyOXRKSzVyPUG3N{43PiCwTR?=	Ml;YV2FPT0WU
BB49-HNC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HVUWlEPTB;MUezMlgyKG6P	MWHTRW5ITVJ?
GMS-10	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF5Mz65OEBvVQ>?	NU[yeXVPW0GQR1XS
NCI-H2052	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnsdHNJUUN3ME2xO\|QvQSCwTR?=	M4XHZnNCVkeHUh?=
SW626	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjrXJVxUUN3ME2xO\|YvODZibl2=	MnL6V2FPT0WU
MDA-MB-415	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPwbld6UUN3ME2xO\|YvPjFibl2=	MkTOV2FPT0WU
Saos-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULIR2dNUUN3ME2xO\|kvOzVibl2=	M4D4W3NCVkeHUh?=
DK-MG	NVeze2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzRSXRKSzVyPUG4NE4{KG6P	MVHTRW5ITVJ?
SNU-C2B	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF6MD63N{BvVQ>?	M{W0enNCVkeHUh?=
A427	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTuTWM2OD1zOEKuOVchdk1?	NG\3PZhUSU6JRWK=
KP-N-YS	M3W3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlf4TWM2OD1zOEWgcm0>	MYjTRW5ITVJ?
J82	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHuZolEUUN3ME2xPFUvOThibl2=	M{\zeXNCVkeHUh?=
LS-411N	M2[2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXtUoRKSzVyPUG4O{4zQCCwTR?=	MUPTRW5ITVJ?
HCC1937	NUHMR3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF6Nz60PUBvVQ>?	NF:0SG1USU6JRWK=
OE33	Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHPWndHUUN3ME2xPFgvQTdibl2=	MYLTRW5ITVJ?
NB7	M1iwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfzPJJKSzVyPUG4PU45QSCwTR?=	MlzRV2FPT0WU
SW684	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPY[GJKSzVyPUG5Ok4yOyCwTR?=	M{fTOHNCVkeHUh?=
HT-144	NIP1R2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPzc2xKSzVyPUG5Ok4yPSCwTR?=	NUnsUZZ2W0GQR1XS
SK-MEL-30	M{TKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULu[48yUUN3ME2xPVYvOiCwTR?=	NEPISlVUSU6JRWK=
DBTRG-05MG	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkW2TWM2OD1zOUiuOFchdk1?	MULTRW5ITVJ?
NCI-H1395	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTF7OD64OUBvVQ>?	M2DPZ3NCVkeHUh?=
NCI-H2122	NHf6XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJyMD61PUBvVQ>?	NVnsNGpSW0GQR1XS
no-10	NEXHUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLDTWM2OD1{MEGuNFQhdk1?	NX;S[pJqW0GQR1XS
SW48	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPVUZJCUUN3ME2yNFEvOzFibl2=	NWL1SJdnW0GQR1XS
NCI-H1650	MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTwRnh3UUN3ME2yNFQvODFibl2=	NYTpRnpYW0GQR1XS
MZ1-PC	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrTTWM2OD1{MEWuOVghdk1?	NHPvflBUSU6JRWK=
U-266	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfvN\|JKSzVyPUKwOU44QSCwTR?=	NInJ[XdUSU6JRWK=
CAS-1	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkS4TWM2OD1{MEeuOFQhdk1?	NF3SZpJUSU6JRWK=
AU565	NYrOVGtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDtZmFKSzVyPUKxNk45OiCwTR?=	M1jVSnNCVkeHUh?=
UACC-257	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTVXHBWUUN3ME2yNVMvQTlibl2=	MVXTRW5ITVJ?
CAL-27	NUjIT5VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJzNz6wOUBvVQ>?	NX3YdXpYW0GQR1XS
NCI-H23	M4TnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HYR2lEPTB;MkG5MlM{KG6P	MV7TRW5ITVJ?
TE-6	NGnYO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInxUI5KSzVyPUKxPU43QCCwTR?=	M3LiRXNCVkeHUh?=
TGBC24TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjQOnN6UUN3ME2yNlIvOTdibl2=	MljqV2FPT0WU
TE-1	NXnQUFByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDL[29oUUN3ME2yNlIvQDhibl2=	M{\XfnNCVkeHUh?=
RCC10RGB	NFP6TZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVq4eI9JUUN3ME2yNlQvOTlibl2=	MVrTRW5ITVJ?
NCI-H596	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDRc3FKSzVyPUKyPE4zOiCwTR?=	M1G4UXNCVkeHUh?=
SW954	M1XKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJ\|Mz64N{BvVQ>?	NGjRfZBUSU6JRWK=
NCI-H2087	M1\6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zIfmlEPTB;MkO0MlUyKG6P	Mn\HV2FPT0WU
SK-PN-DW	NFzpUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJ\|NT6xPUBvVQ>?	M2T3cXNCVkeHUh?=
KM12	NHPqdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\6TWM2OD1{M{WuO{BvVQ>?	NIXtWpBUSU6JRWK=
BT-474	NX;IZngxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJ\|NT63N{BvVQ>?	NU\NZlNIW0GQR1XS
IST-MES1	NFPi[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrCTWM2OD1{M{[uOVchdk1?	M3nNNXNCVkeHUh?=
HT-1197	M{XtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJ\|OD6wPUBvVQ>?	MWHTRW5ITVJ?
CAL-54	M2eye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnewTWM2OD1{M{iuOFkhdk1?	NF[4PWVUSU6JRWK=
NB10	NYHFRlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPMOo1ZUUN3ME2yOFAvODZibl2=	MlftV2FPT0WU
PANC-10-05	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4WzUGlEPTB;MkS1MlU3KG6P	NXflWJBpW0GQR1XS
NCI-H522	NIPUN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTPPIx3UUN3ME2yOFgvOzFibl2=	MXzTRW5ITVJ?
A388	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ2OT64NkBvVQ>?	NWOwfXQ3W0GQR1XS
GOTO	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fzWWlEPTB;MkWwMlI6KG6P	MXzTRW5ITVJ?
KLE	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfUU4lrUUN3ME2yOVEvQDdibl2=	MWDTRW5ITVJ?
KYSE-520	NHzBcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fCZmlEPTB;MkWyMlg3KG6P	M{P1d3NCVkeHUh?=
HCE-4	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\FO4s5UUN3ME2yOlIvPSCwTR?=	NIHlSm5USU6JRWK=
KURAMOCHI	NXvMNphFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\GW5VCUUN3ME2yOlUvQSCwTR?=	Mo\nV2FPT0WU
HCC38	NUTMUpppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvUTWM2OD1{Nk[uOFghdk1?	MVPTRW5ITVJ?
FADU	NHvoNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXhR5pKSzVyPUK2Ok43OyCwTR?=	Mn;RV2FPT0WU
CW-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVuwRXdXUUN3ME2yOlkvQTZibl2=	MoGxV2FPT0WU
L-428	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXkeXZKSzVyPUK3OU4yPSCwTR?=	NFqzcG1USU6JRWK=
HCC1569	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVThdGZ2UUN3ME2yO\|UvQDRibl2=	NIPJdZNUSU6JRWK=
NCI-H810	NYLOWXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17GV2lEPTB;Mke4MlMyKG6P	NH;ZPVRUSU6JRWK=
LB771-HNC	NYnycY5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXrTWM2OD1{OEWuPFQhdk1?	NH3aNppUSU6JRWK=
LCLC-103H	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3FU49KSzVyPUK4OU46QSCwTR?=	Mnq4V2FPT0WU
EFO-21	NFOzVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH5OXBKSzVyPUK4O{43QCCwTR?=	MmW0V2FPT0WU
CAL-72	NGXjW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j5UmlEPTB;MkmzMlE6KG6P	NIPJRVhUSU6JRWK=
SCC-9	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;jTJFrUUN3ME2yPVMvOjJibl2=	NHizS3hUSU6JRWK=
COLO-829	NWfJb213T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvRZphDUUN3ME2yPVYvPSCwTR?=	NEjCPItUSU6JRWK=
U-87-MG	NVjrSWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTNyMD63N{BvVQ>?	MojBV2FPT0WU
MZ7-mel	NGP5T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGexe41KSzVyPUOyN{44PiCwTR?=	NVK3d3FyW0GQR1XS
NCI-H1770	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTN{Nj63OEBvVQ>?	MVzTRW5ITVJ?
ChaGo-K-1	NI\3cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXGyT2htUUN3ME2zNlgvOSCwTR?=	NGHPeIpUSU6JRWK=
SiHa	NFrwWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi5OVdoUUN3ME2zNlkvOjRibl2=	NUjqZ4hOW0GQR1XS
NCI-SNU-5	NFjwRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[1XGFSUUN3ME2zN\|YvPzdibl2=	Ml\xV2FPT0WU
DJM-1	NV6yc5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXZTWM2OD1\|NECuN\|Mhdk1?	MW\TRW5ITVJ?
OE19	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPjWFMzUUN3ME2zOFAvPTNibl2=	M2LjSnNCVkeHUh?=
NCI-H1651	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLEZWFKSzVyPUO0OE4yQCCwTR?=	NVTXXIp1W0GQR1XS
COLO-792	M{mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7EbVM3UUN3ME2zOVQvPDJibl2=	MYjTRW5ITVJ?
ACHN	NVT6SHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTN3Nj63NUBvVQ>?	NXjnNVViW0GQR1XS
TH-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTN5OT65OUBvVQ>?	MnPKV2FPT0WU
HT-1376	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nEOWlEPTB;M{i0Mlg5KG6P	MlnlV2FPT0WU
RH-18	NFS3[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLDTWM2OD1\|OUSuO\|Qhdk1?	M2XvO3NCVkeHUh?=
NB6	NEfJfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n1PWlEPTB;M{m2MlY3KG6P	Mn3KV2FPT0WU
COLO-320-HSR	NH7QbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmOwTWM2OD12MEOuN\|chdk1?	MYXTRW5ITVJ?
UACC-893	NHHsRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLjeHdKSzVyPUSwOk41PyCwTR?=	NXrod2FkW0GQR1XS
DSH1	NUHUV3JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDLNIlKSzVyPUSwOk46OSCwTR?=	MlHGV2FPT0WU
TE-10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X2PWlEPTB;NEC3MlAyKG6P	NX\X[ZdJW0GQR1XS
HCC70	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XrRmlEPTB;NEC5MlIyKG6P	NVXDc4Z1W0GQR1XS
TGBC11TKB	NEXtRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnflTWM2OD12MUCuN\|Mhdk1?	MkXNV2FPT0WU
NCI-H727	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTRzMj6xNUBvVQ>?	Ml;YV2FPT0WU
ALL-PO	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXwOHRzUUN3ME20NVUvPjlibl2=	NYPJblhCW0GQR1XS
ABC-1	M2e4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTR{MD60OUBvVQ>?	M2rvfHNCVkeHUh?=
NCI-H69	NV;yVHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3y5NmlEPTB;NEK2Mlc3KG6P	MonKV2FPT0WU
GP5d	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7WV3FKSzVyPUSzOE41OSCwTR?=	NVfJeIh5W0GQR1XS
UMC-11	NF;TbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTnOWNKSzVyPUS1PE4{PiCwTR?=	M13m[XNCVkeHUh?=
RMG-I	NYDtfmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFflWVJKSzVyPUS2O{42PiCwTR?=	NFm3ToVUSU6JRWK=
YAPC	M1W3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jpNmlEPTB;NEmwMlYhdk1?	M3PZXnNCVkeHUh?=
LS-1034	NI\VeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETsNHBKSzVyPUS5NU4xPiCwTR?=	MYTTRW5ITVJ?
RCM-1	M1H1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTR7Nj62PEBvVQ>?	MoDuV2FPT0WU
HCC1954	NELzOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTVzMj61JI5O	MnvGV2FPT0WU
SK-MEL-24	NVvJcXJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvBWGJKSzVyPUWxOk42OSCwTR?=	MnK2V2FPT0WU
NB12	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;xV5A3UUN3ME21NlgvPDJibl2=	NUL0fGJQW0GQR1XS
SW756	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrLd2VKSzVyPUW1OE46PiCwTR?=	MkXQV2FPT0WU
HCC1187	NIXVboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PjZ2lEPTB;NUe1Mlg{KG6P	MVHTRW5ITVJ?
NCI-H2342	M2[yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjsSmx3UUN3ME21PVAvOzlibl2=	NV3aOIpbW0GQR1XS
NCI-H2291	M1LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\kTWM2OD13OUiuN\|Ehdk1?	MWXTRW5ITVJ?
OVCAR-3	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33wXGlEPTB;NUm4Mlk3KG6P	MU\TRW5ITVJ?
MHH-NB-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXZUGhsUUN3ME22NlkvODFibl2=	NXi4SW5GW0GQR1XS
SAS	NX7OfJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknyTWM2OD14NUKuOlchdk1?	MVPTRW5ITVJ?
COLO-824	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXWTWM2OD14OEmuN\|chdk1?	NGixToNUSU6JRWK=
HCC1395	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjUfYJ2UUN3ME22PVgvPSCwTR?=	MmTXV2FPT0WU
COLO-668	M36xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXSO4dyUUN3ME23NFYvOSCwTR?=	NWfFRotqW0GQR1XS
NCI-H226	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLpSIZKSzVyPUewO{45KG6P	Ml;vV2FPT0WU
NB17	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTd{MT63OUBvVQ>?	MlLnV2FPT0WU
SW1463	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[wUY9KSzVyPUezPU4yQSCwTR?=	NF3mN3ZUSU6JRWK=
TGW	M4TJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTd4MD6xOUBvVQ>?	MnTyV2FPT0WU
NCI-H526	NVHIOWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTBe\|lUUUN3ME24NlMvPTNibl2=	NXzJfG9{W0GQR1XS
COR-L88	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPFfllKSzVyPUi0PE4yOiCwTR?=	M3XhV3NCVkeHUh?=
NCI-H441	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTh7NT6yNkBvVQ>?	NIqzeZBUSU6JRWK=
NCI-H630	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr5OGtKSzVyPUmxNk46PiCwTR?=	MonHV2FPT0WU
Mo-T	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTl2Nz64PEBvVQ>?	NVW2fGdHW0GQR1XS
JAR	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fXUGlEPTB;OUW2MlI1KG6P	MmTaV2FPT0WU
NCI-H1838	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwMEKzPFgh\|ryP	NHjwd2hUSU6JRWK=
DoTc2-4510	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1T3RmlEPTB;MT6wO\|M4PiEQvF2=	NInRTGRUSU6JRWK=
MKN28	NGf0cWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS3W\|ZKSzVyPUGuNFkxOjRizszN	MYDTRW5ITVJ?
HuP-T3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGG5W5RKSzVyPUGuNVE6ODVizszN	NGnYeIZUSU6JRWK=
TE-9	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwMUK5O\|Mh\|ryP	M{\re3NCVkeHUh?=
NY	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnETWM2OD1zLkG2O\|kzKM7:TR?=	MVnTRW5ITVJ?
HT55	M4HCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXv0UXh1UUN3ME2xMlMyOzR2IN88US=>	M4rtVHNCVkeHUh?=
SW837	M1rNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrvS4hKSzVyPUGuN\|I6PzhizszN	NY[3OYZRW0GQR1XS
NCI-H2029	NV\Z[GdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPkN2R5UUN3ME2xMlQyPzlzIN88US=>	M3PtUXNCVkeHUh?=
IST-SL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFwNESyOEDPxE1?	NEjyTlBUSU6JRWK=
COLO-741	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe0Z3VUUUN3ME2xMlQ6PzdzIN88US=>	NUHJUWhUW0GQR1XS
LU-65	M3[yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjpTWM2OD1zLk[yNlQ6KM7:TR?=	MYTTRW5ITVJ?
NCI-H1304	NV;5S5UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjyTWM2OD1zLk[1OFk5KM7:TR?=	M3fN[HNCVkeHUh?=
KARPAS-299	NXq1PVFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7MTWM2OD1zLke5OFc6KM7:TR?=	MV;TRW5ITVJ?
NCI-H358	NYPKTmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXBbIlKSzVyPUGuPVU2ODNizszN	M3fFO3NCVkeHUh?=
OAW-28	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDpco97UUN3ME2yMlA3QTF7IN88US=>	MnfUV2FPT0WU
C8166	NUDX[GZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvvfI9qUUN3ME2yMlY{Ozl{IN88US=>	MkT4V2FPT0WU
COLO-678	M1HyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zC[mlEPTB;Mj64N\|c3QCEQvF2=	MnvjV2FPT0WU
SK-N-DZ	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\KTI94UUN3ME2yMlg3OzhzIN88US=>	MUTTRW5ITVJ?
NCI-H82	M3\lcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInDZZNKSzVyPUKuPVA{PjlizszN	NWfUeHF3W0GQR1XS
JVM-2	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnGxTWM2OD1\|LkCzNVg5KM7:TR?=	NVTJO3RuW0GQR1XS
SW1116	NGfsW\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTNwMEW0NVEh\|ryP	NVX0NFl6W0GQR1XS
MDA-MB-453	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG1SlYxUUN3ME2zMlExPDN7IN88US=>	NGm3dXlUSU6JRWK=
Calu-6	NFrDVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3WxWmlEPTB;Mz6xPVk4KM7:TR?=	MnexV2FPT0WU
SHP-77	NWnrcoY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H1R2lEPTB;Mz61Nlgh\|ryP	M{Pze3NCVkeHUh?=
Capan-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3Lb5BKSzVyPUSuN\|I2QDFizszN	MljuV2FPT0WU
SW948	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfnTWM2OD12Lke0O\|c6KM7:TR?=	NYHldYVMW0GQR1XS
HDLM-2	M1z4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2ezS2lEPTB;NT6wO\|czPSEQvF2=	NFHYTZlUSU6JRWK=
LAN-6	M4rodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nhdmlEPTB;Nj6yNVQ6PSEQvF2=	M4TBSHNCVkeHUh?=
LU-135	MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC4TWM2OD14LkSzNFc4KM7:TR?=	MnXMV2FPT0WU
T84	M1[xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jNd2lEPTB;Nj65PFY1KM7:TR?=	M1Lxb3NCVkeHUh?=
CAPAN-1	NHzWO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7kRmc2UUN3ME23MlYzOjN\|IN88US=>	MV7TRW5ITVJ?
SW1417	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3uVIg{UUN3ME23MlkyPzNzIN88US=>	MYXTRW5ITVJ?
BALL-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nTVmlEPTB;OD61NFQxQSEQvF2=	MnfoV2FPT0WU
HT-29	M{i2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTlwMEe1PVkh\|ryP	M1[xT3NCVkeHUh?=
C3A	M3jGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jMdmlEPTB;OT64PFM6PCEQvF2=	NV;ze49pW0GQR1XS
NCI-H1993	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjVNpdKSzVyPUGwMlUxQDFizszN	M1fzeXNCVkeHUh?=
SK-MEL-1	NYriWXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFzLk[yPFkh\|ryP	NHyxVZZUSU6JRWK=
DU-145	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7NWGF1UUN3ME2xOE42ODV{IN88US=>	MmDuV2FPT0WU
KP-N-YN	M3jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfRPJRyUUN3ME2xOE42OTB\|IN88US=>	MnjwV2FPT0WU
CCRF-CEM	NEjCTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHT0ZnRKSzVyPUG0Mlc5ODlizszN	M3LBd3NCVkeHUh?=
ZR-75-30	NHPuNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHhTWM2OD1zNj6zN\|A{KM7:TR?=	Moi0V2FPT0WU
A673	NY[0[lBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfiTWM2OD1{MD61OVA4KM7:TR?=	MWLTRW5ITVJ?
K-562	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzJWnBXUUN3ME2yPE41OTh\|IN88US=>	MkfFV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-BEZ235

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)